Many of the most important breakthroughs in the history of medicine were the result of chance or serendipity. Researchers often stumbled upon revolutionary discoveries while looking for something entirely different. X-rays by Roentgen, penicillin by Fleming, insulin by Banting—just to name a few. All born from sudden intuition, detours, or fortunate coincidences.
Today, the rise of Artificial Intelligence (AI) has the potential to amplify these very moments of discovery accelerating and enhancing the development of new therapeutic options. AI can analyse vast volumes of data, detect hidden patterns, and generate hypotheses that human minds alone would struggle to uncover.
Let’s take a closer look at how AI is transforming the medical field, and where it’s making the biggest impact, opening up possibilities we couldn’t have imagined just a few years ago.
Faster, more accurate drug discovery
Traditionally, drug discovery is a long and costly process: bringing a new drug to market can take up to 15 years and billions of dollars. However, this is changing, thanks to the growing use of AI. With machine learning (ML) and deep learning (DL) algorithms, AI can analyse massive biological databases and model drug-target interactions with unprecedented accuracy, dramatically speeding up the data analysis phase.
This enables the discovery of new therapeutic targets and allows researchers to optimise drug formulations in a fraction of the time required by traditional methods. But AI’s contribution doesn’t stop there. Once promising molecules are identified, they must be tested for efficacy and safety, an area where AI proves particularly valuable. ML techniques can analyse thousands of chemical compounds in seconds, reducing the number of required tests and increasing the likelihood of identifying molecules worth advancing into clinical trials.
AI can also predict potential side effects and toxicity levels early in development, helping to reduce the risk of late-stage failures.
Digital vaccines and new therapeutic horizons
Since Jenner’s smallpox vaccine in 1796, vaccine development has come a long way. In recent years, the introduction of AI has sparked a revolution. One major shift has come with Reverse Vaccinology: instead of cultivating pathogens in a lab, researchers identify antigens using bioinformatics and genomic sequencing. This approach accelerates development and enables the creation of complex vaccines, such as the one for meningococcus B.
During the COVID-19 pandemic, AI took on an even more crucial role with the development of mRNA vaccines, where the antigen is a nucleotide sequence. AI helped rapidly identify promising gene sequences and suggested ways to optimise mRNA stability and immunogenicity. What once took years of R&D can now happen in months.
What does the next decade hold? As AI, machine learning, and neural networks become more tightly integrated, we’ll be able to design antigens entirely in silico eliminating the need for preliminary lab experiments. Genomic data for most microorganisms will be stored in databases, and AI will optimise antigen selection based on factors like immunogenicity, surface exposure, and genetic variability.
Toxicity, safety, and immunogenicity tests will be conducted on organoids-on-a-chip bioengineered models that simulate human tissue, generate massive amounts of data, and provide reliable predictions about dosage, formulation, timing, and even clinical efficacy.
In this scenario, vaccines that once seemed impossible may become reality. We could develop effective solutions against chronic diseases, resistant infections, cancer, and even neurodegenerative conditions. Improved vaccines for malaria, personalised strategies for HIV, and new formulations for untreatable conditions are on the horizon. The convergence of AI, computational biology, and digital innovation will take us far beyond what we currently think is possible. The future of vaccines won’t just be faster, it will be more precise, more predictive, and potentially universal.
AI-Powered personalised treatment
One of the most promising applications of AI in healthcare is personalised medicine. By combining a patient’s genetic, clinical, and environmental data, AI can develop tailored treatment plans maximising therapeutic effectiveness and minimising side effects.
For instance, genomic data analysis can identify which patients are likely to respond to specific drugs, while information about environmental and lifestyle factors can help build more effective treatment protocols.
AI is also transforming diagnostics. It’s used to detect diseases in their earliest stages when the chances of recovery are highest. Advanced DL algorithms can analyse medical images like X-rays and MRIs to identify subtle signs of illness that may be missed by the human eye, improving early detection and treatment outcomes.
Challenges and considerations
While AI is revolutionising medical research, there are still several obstacles to large-scale adoption. One major issue is data quality. AI relies on massive volumes of data to learn and make accurate predictions, but biological and clinical data are often incomplete, inconsistent, or low quality, which can undermine model reliability.
Another key challenge is regulation. Introducing new technologies into medicine inevitably calls for updated policies to ensure safety and avoid harm to patients. Current regulatory frameworks can’t always keep up with the rapid pace of AI development, leading to legal uncertainties and slow approval processes.
Finally, model validation remains one of the most complex issues. It’s a long, expensive process, but an essential one to ensure safety and reliability in clinical trials.
FOR FURTHER READING